NEW YORK, NY / ACCESSWIRE / February 4, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Sleep Number Corporation (NASDAQ:SNBR)
CONTACT JAKUBOWITZ ABOUT SNBR:
https://claimyourloss.com/securities/sleep-number-corporation-loss-submission-form/?id=23388&from=1
Class Period: February 18, 2021 - July 20, 2021
Lead Plaintiff Deadline: February 14, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) Sleep Number had suffered a severe disruption in its supply chain for foam as a result of Winter Storm Uri; (b) Sleep Number did not have in place the supply chain flexibility, redundancies and fail-safes, as had been represented to investors, sufficient to offset the foam supply disruption caused by Winter Storm Uri; (c) because foam was a necessary component for Sleep Number's production of its primary mattress products, Sleep Number's ability to timely fulfill customer orders had been materially impaired; (d) as a result of (a)-(c) above, Sleep Number was unable to meet surging customer demand for the Company's products; and (e) as a result of (a)-(d) above, Sleep Number had been forced to delay mattress shipments to end consumers, pushing millions of dollars' worth of sales into subsequent quarters and negatively impacting the Company's financial results.
Bright Health Group, Inc. (NYSE:BHG)
CONTACT JAKUBOWITZ ABOUT BHG:
https://claimyourloss.com/securities/bright-health-group-inc-loss-submission-form/?id=23388&from=1
This lawsuit is on behalf of all persons and entities other than defendants that purchased or otherwise acquired: (a) Bright Health common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about June 24, 2021; and/or (b) Bright Health securities between June 24, 2021 and November 10, 2021.
Lead Plaintiff Deadline: March 7, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Bright Health had overstated its post-IPO business and financial prospects; (ii) the Company was ill-equipped to handle the impact of COVID-19-related costs; (iii) the Company was experiencing a decline in premium revenue because of a failure to capture risk adjustment on newly added lives; (iv) all the foregoing was reasonably likely to have a material negative impact on Bright Health's business and financial condition; and (v) as a result, the documents issued in connection with the IPO and Defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
Talis Biomedical Corporation (NASDAQ:TLIS)
CONTACT JAKUBOWITZ ABOUT TLIS:
https://claimyourloss.com/securities/talis-biomedical-corporation-loss-submission-form/?id=23388&from=1
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Talis common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's February 2021 initial public offering.
Lead Plaintiff Deadline: March 8, 2022
According to the lawsuit, documents that the Company issued in connection with its IPO failed to disclose to investors: (1) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis's Emergency Use Authorization application for Talis One COVID-19 test; (2) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) that, as a result, the Company's commercialization timeline would be significantly delayed; and (4) that, as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/687402/Lawsuits-Filed-Against-SNBR-BHG-and-TLIS-Jakubowitz-Law-Pursues-Shareholders-Claims